Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged >=12 Years with Reported Contact with COVID-19 Cases, February - September 2021

Jessie Chung; Sara Kim; Edward A Belongia; Huong Q McLean; Jennifer P King; Mary Patricia Nowalk; Richard K Zimmerman; Krissy Moehling Geffel; Emily Toth Martin; Arnold Monto; Lois E Lamerato; Manjusha Gaglani; Eric Hoffman; Marcus Volz; Michael L. Jackson; Lisa A Jackson; Manish M Patel; Brendan Flannery.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21267928

Documentos relacionados

  1. Vaccine effectiveness against COVID-19 among symptomatic persons aged ≥12 years with reported contact with COVID-19 cases, February-September 2021.
  2. Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.
  3. Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.
  4. Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.
  5. Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following High-Risk Exposure.
  6. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.
  7. Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021.
  8. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers-Zambia, July 2020.
  9. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
  10. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.